I went to the company website where there is a picture of a golden retriever and suggested the dog should replace Junius and the stock price would go up. Even better they should switch management with sgen for 3 months and watch us soar.
same with the CAR-T stocks, they are all way overvalued and according to someone I spoke with yesterday, the price of the drugs will be $200K. See DNDN for the future of CAR-T.
As for IMGN, shareholders have no idea what is going on, management is absent and negligent to say the least.
It is hilarious, and very sad. For this stock to move up it is all on the management now. Ted Knight voice "well...we are waiting"
Alnylam market cap at 7.5B; IMGN at 550M. Is RNAi ever gonna work?
I thought FDA banned snake oil very early on. Why are there still so many biotech companies peddling snake oil? That's right...they just need to be somewhat properly labelled; they don't really need to work as advertised. Is IMGN also a snake oil company that we have invested in?
I think there is a reasonable chance they could be bought out at these levels in the first half of this year. Also a reasonable chance some good data comes out which could be the catalyst to shoot back up / counter the bad data that came out last month.
bioimmunomabman has been beating that drum for about a year now, and I agree with him. Nothing is going to change though. I think the bright future that was once there for IMGN is starting to fade.
Everyone is losing hope in this POS/
Wishful thinking, this stock is a big time POS. Coming back to this stock was the biggest mistake I've ever made trading.
what about 289? When DJ first introduced 289 you would have thought is cured every cancer. Maybe he was listening to the wrong people and just doesn't know any better, but he's the CEO and he has zero credibility now with shareholders and the street. If DJ and the BOD are not buying stock at this level, they need to sell and get out, or just get out.
Immunogen announces 2015 outlook for product pipeline (IMGN) : Co announced expectations for its product pipeline in 2015 that Company management will be discussing at the J.P. Morgan Healthcare Conference.
Wholly Owned Product Candidates
Expected 2015 events include:
Presentation of updated clinical findings -- 2Q2015.
Initiation of Phase II testing in FRa-positive ovarian cancer or endometrial cancer, or both, with potential for accelerated registration program(s) if the data allow -- 2H2015.
Initiation of assessment in combination regimens for the treatment of FRa-positive ovarian cancer.
IMGN529 -- the first ADC for B-cell malignancies with an antibody demonstrating potent anticancer activity preclinically, and the first to target CD37.
Expected 2015 events include:
Selection of recommended Phase II dose -- 1H2015.
Start of initial efficacy testing, including as a treatment for relapsed/refractory diffuse large B-cell lymphoma and for chronic lymphocytic leukemia -- 2Q/3Q2015.
Presentation of updated clinical data -- 2H2015
ImmunoGen will report the financial results on January 30, 2015 for the quarter ended December 31, 2014, the second quarter of the Company's 2015 fiscal year, but noted that it ended the quarter with approximately $107 MM in cash and marketable securities, and had no debt.
Sentiment: Strong Buy
What's more curious is why Takeda didn't pick SGEN. ADC deals with IMGN and SGEN must be getting too pricey to do these days.
With the lack of damage control and lack of insider buying from Junius and the boys when the pps was sub6, I am now joining you in wanting to throw them all overboard.